Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older, with lymphoid malignancies of B-cell origin including:~  1. Indolent / aggressive B-cell non-Hodgkin's lymphoma (NHL)~     * EXCLUDING: Burkitt's lymphoma and precursor B lymphoblastic leukemia/lymphoma~    * INCLUDING: any non-Hodgkin's B cell malignancy such as chronic lymphocytic leukemia (CLL) and rare non-Hodgkin's B- cell subtypes such as hairy cell leukemia, Waldenström macroglobulinemia (WM), mantle cell leukemia (MCL), and transformed NHL histologies~ 2. Hodgkin's lymphoma (HL)~* Life expectancy of 12 weeks or longer~* Subject must have received ≥ 1 prior treatment regimen(s)~* The subject must not be a candidate for potentially curative therapy including hematopoietic stem cell transplantation, except where one of the standard therapy regimen combinations may be used prior to transplantation per standard medical practice~Exclusion Criteria:~* Has history of brain metastasis, spinal cord compression (unless treated, asymptomatic, and stable on most recent imaging and enrolling in expansion cohort), or lymphoma involving the central nervous system (CNS)~* Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3 (≥ 2 during dose escalation)~* Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or currently receiving immunosuppressive therapy following allogeneic transplant~* Received autologous hematopoietic stem cell transplant within the last 3 months~* Inadequate marrow reserve assessed by hematologic laboratory parameters~* Inadequate renal or liver function~* Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parsaclisib 5 mg QD (Type: EXPERIMENTAL): Parsaclisib 5 milligrams (mg) as an oral tablet once a day (QD) in 21-day treatment cycles
- Parsaclisib 10 mg QD (Type: EXPERIMENTAL): Parsaclisib 10 mg as oral tablets QD in 21-day treatment cycles
- Parsaclisib 15 mg QD (Type: EXPERIMENTAL): Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles
- Parsaclisib 20 mg QD (Type: EXPERIMENTAL): Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles
- Parsaclisib 30 mg QD (Type: EXPERIMENTAL): Parsaclisib 30 mg as oral tablets QD in 21-day treatment cycles
- Parsaclisib 45 mg QD (Type: EXPERIMENTAL): Parsaclisib 45 mg as oral tablets QD in 21-day treatment cycles
- Parsaclisib 20 mg + itacitinib (INCB039110) 300 mg (Type: EXPERIMENTAL): Parsaclisib 20 mg as oral tablets QD and itacitinib (INCB039110) 300 mg as oral tablets QD in 21-day treatment cycles
- Parsaclisib 30 mg + itacitinib (INCB039110) 300 mg (Type: EXPERIMENTAL): Parsaclisib 30 mg as oral tablets QD and itacitinib (INCB039110) 300 mg as oral tablets QD in 21-day treatment cycles
- Parsaclisib 15 mg QD + R-ICE (Type: PLACEBO_COMPARATOR): Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles. R-ICE was a standard-of-care chemotherapy combination administered at the following doses: rituximab 375 milligrams per meters squared (mg/m\^2) intravenously (IV) on Day 1 and Day 2 of Cycle 1 and on Day 1 of Cycles 2 and 3, ifosfamide 5000 mg/m\^2 IV on Day 3 of each cycle, carboplatin area under the curve (AUC) = 5 (maximum dose 800 mg) IV on Day 3 of each cycle, and etoposide 100 mg/m\^2 or at doses consistent with institutional practice with approval from the medical monitor on Days 3 and 5 of each cycle. Each cycle was 21 days in duration
- Parsaclisib 20 mg QD + R-ICE (Type: PLACEBO_COMPARATOR): 20 mg as oral tablets QD in 21-day treatment cycles. R-ICE was a standard-of-care chemotherapy combination administered at the following doses: rituximab 375 mg/m\^2 IV on Day 1 and Day 2 of Cycle 1 and on Day 1 of Cycles 2 and 3, ifosfamide 5000 mg/m\^2 IV on Day 3 of each cycle, carboplatin AUC = 5 (maximum dose 800 mg) IV on Day 3 of each cycle, and etoposide 100 mg/m\^2 or at doses consistent with institutional practice with approval from the medical monitor on Days 3 and 5 of each cycle. Each cycle was 21 days in duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete